Specialties & Topics
- Arthritis/Rheumatic Disease
- Breast Cancer
- GERD/Peptic Ulcers
December 5th, 2009
Dr. Robert Centor of the University of Alabama at Birmingham believes that the paradigm for treating pharyngitis in adolescents and young adults must change. Listen to our conversation and hear why. Here are this week’s links: Interview: Commentary Urges ‘Expanding the Diagnostic Paradigm of Pharyngitis’ in Young People Robert Centor’s blog — “Medrants” News stories: [...]
July 2nd, 2009
Scanning patients on bisphosphonates within the first 3 years of therapy is just wasted effort, and may even be misleading clinically. That’s what researchers conclude after reanalysis of FIT trial data on some 6500 women taking either alendronate or placebo. Prof. Les Irwig of the University of Sydney talks about his team’s findings and what [...]
May 8th, 2009
We talk about writing with Danielle Ofri, editor of the Bellevue Literary Review, author of “Singular Intimacies: Becoming a Doctor at Bellevue” and “Incidental Findings: Lessons from My Patients in the Art of Medicine,” and an attending physician at Bellevue. I figured you could do with less information about influenza. If you’ve got a reaction, [...]
March 13th, 2009
Podcast 34: An interview with Cheryl Bushnell of Wake Forest about her paper in BMJ concerning migraines during pregnancy and the possibility of their relation to strokes and other vascular problems.
BMJ‘s paper on the possible association of migraine during pregnancy and stroke (and other vascular problems) is the focus of this week’s interview. We speak with first-author Dr. Cheryl Bushnell. And then there’s the week’s news, plus a message from a listener! It could have been you, if only you’d called 1-617-440-4374 and made a [...]
December 5th, 2008
Podcast 22: Interview with Aaron Kesselheim about his meta-analysis of the efficacy of proprietary versus generic cardiovascular drugs.
This week, in addition to the usual news roundup, we talk with Dr. Aaron Kesselheim about his JAMA paper on the equivalence between proprietary and generic cardiovascular drugs. The data and the editorials are often at odds on this question. Have a listen, and if you want to react to any of this, call 1-617-440-4374. [...]